Analysis of antibody and cytokine markers for leprosy nerve damage and reactions in the INFIR cohort in India

PLoS Neglected Tropical Diseases

Volumn 5, Issue 3, 2011, Pages

  Jadhav, Rupendra ^a   Suneetha, Lavanya ^b   Kamble, Ravindra ^a   Shinde, Vidyagouri ^a   Devi, Karuna ^b   Chaduvula, Meheri Vani ^b   Raju, Renuka ^b   Suneetha, Sujai ^b   Nicholls, Peter G ^c   van Brakel, Wim H ^d   Lockwood, Diana N J ^e  

^a India   (India)

^b LEPRA Society   (India)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d ROYAL TROPICAL INSTITUTE   (Netherlands)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CERAMIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOARABINOMANNAN; MYCOBACTERIUM ANTIGEN; PHENOLIC GLYCOLIPID; PROTEIN ANTIBODY; PROTEIN S 100; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; AUTOANTIBODY; BACTERIUM ANTIBODY; CYTOKINE; IMMUNOGLOBULIN G;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INDIA; LEPROSY; MAJOR CLINICAL STUDY; NERVE INJURY; RISK FACTOR; SKIN MANIFESTATION; BLOOD; COHORT ANALYSIS; PATHOLOGY; PERIPHERAL NEUROPATHY;

ANTIBODIES, BACTERIAL; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INDIA; LEPROSY; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 79953771906     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000977     Document Type: Article

References (31)

1. Scollard DM, (2008) The biology of nerve injury in leprosy. Lepr Rev 79: 242-253.
2. Lockwood DN, Colston MJ, Khanolkar-Young SR, (2002) The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg 66: 409-415.
3. Wemambu SNC, Turk JL, Waters MFR, Rees RJW, (1969) Erythema nodosum leprosum: a clinical manifestation of Arthrus phenomenon. Lancet 2: 933-935.
4. Richardus JH, Nicholls PG, Croft RP, Withington SG, Smith WC, (2004) Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. Int J Epidemiol 33: 337-343.
5. Saunderson P, (2000) The epidemiology of reactions and nerve damage. Lepr Rev71 (Suppl): S106-110.
6. Schreuder PA, (1998) The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. II. Reactions. Int J Lepr Other Mycobact Dis 66: 159-169.
7. Cho SN, Cellona RV, Villahermosa LG, Fajardo TT Jr, Balagon MV, et al. (2001) Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy. Clin Diagn Lab Immunol 8: 138-142.
8. Roche PW, Theuvenet WJ, Britton WJ, (1991) Risk factors for type-1 reactions in borderline leprosy patients. Lancet 338: 654-657.
9. Weir RE, Butlin CR, Neupane KD, Failbus SS, Dockrell HM, (1998) Use of a whole blood assay to monitor the immune response to mycobacterial antigens in leprosy patients: a predictor for type 1 reaction onset? Lepr Rev 69: 279-293.
10. Silva EA, Iyer A, Ura S, Lauris JR, Naafs B, et al. (2007) Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health 12: 1450-1458.
11. Dhandayuthapani S, Izumi S, Anandan D, Bhatia VN, (1992) Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Clin Exp Immunol 88: 253-257.
12. Beuria MK, Mohanty KK, Katoch K, Sengupta U, (1999) Determination of circulating IgG subclasses against lipoarabinomannan in the leprosy spectrum and reactions. Int J Lepr Other Mycobact Dis 67: 422-428.
13. Zeballos RS, McPherson RA, (1992) Update of autoantibodies in neurologic disease. Clin Lab Med 12: 61-83.
14. Eustis-Turf EP, Benjamins JA, Lefford MJ, (1986) Characterization of the anti-neural antibodies in the sera of leprosy patients. J Neuroimmunol 10: 313-330.
15. Vemuri N, Mukherjee R, (1991) Immunoreactivity of nerve lipid antigens in leprosy. J Clin Lab Anal 5: 157-161.
16. Thomas BM, Mukherjee R, (1990) Antineural antibodies in sera of leprosy patients. Clin Immunol Immunopathol 57: 420-429.
17. Narayan R, Maheshwari PK, Desikan KV, Harinath BC, (1997) Detection of S-100 protein and anticeramide antibodies in leprosy patients by ELISA. Lepr Rev 68: 117-124.
18. Vemuri N, Viera LM, Taneja KK, Gangal SV, Mukherjee R, (1996) Antisphingolipid antibodies in the sera of leprosy patients. Lepr Rev 67: 95-103.
19. Khanolkar-Young S, Rayment N, Brickell PM, Katz DR, Vinayakumar S, et al. (1995) Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 99: 196-202.
20. Parida SK, Grau GE, Zaheer SA, Mukherjee R, (1992) Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Clin Immunol Immunopathol 63: 23-27.
21. van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, et al. (2005) The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev 76: 14-34.
22. Van Brakel WH, Nicholls PG, Das L, Barkataki P, Maddali P, et al. (2005) The INFIR Cohort Study: assessment of sensory and motor neuropathy in leprosy at baseline. Lepr Rev 76: 277-295.
23. Schwerer B, Meeker HC, Sersen G, Levis WR, (1984) IgM antibodies againstphenolic glycolipid I from Mycobacterium leprae in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Act Leprol 2 (2-4): 394-402.
24. Schuring RP, Richardus JH, Steyerberg EW, Pahan D, Faber WR, et al. (2008) Preventing nerve function impairment in leprosy: validation and updating of a prediction rule. PLoS Negl Trop Dis 2: e283.
25. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P, (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56: 731-740.
26. Selmaj KW, Raine CS, (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-346.
27. Haslett PA, Roche P, Butlin CR, Macdonald M, Shrestha N, et al. (2005) Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis 192: 2045-2053.
28. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G, (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703.
29. Andersson AK, Chaduvula M, Atkinson SE, Khanolkar-Young S, Jain S, et al. (2005) Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun 73: 3725-3733.
30. van Brakel WH, Nicholls PG, Wilder-Smith EP, Das L, Barkataki P, et al. (2008) Early Diagnosis of Neuropathy in Leprosy-Comparing Diagnostic Tests in a Large Prospective Study (the INFIR Cohort Study). PLoS Negl Trop Dis 2: e212.
31. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, et al. (2009) Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report. BMC Infect Dis 9: 75.